Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma
<p><strong>Background and Purpose:</strong><br /> Oxygen-enhanced magnetic resonance imaging (MRI) and T1-mapping was used to explore its effectiveness as a prognostic imaging biomarker for chemoradiotherapy outcome in anal squamous cell carcinoma.</p><br /> <...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2020
|
| _version_ | 1797051185789665280 |
|---|---|
| author | Bluemke, E Bulte, D Bertrand, A George, B Cooke, R Chu, K-Y Durrant, L Goh, V Jacobs, C Ng, SM Strauss, VY Hawkins, MA Muirhead, R |
| author_facet | Bluemke, E Bulte, D Bertrand, A George, B Cooke, R Chu, K-Y Durrant, L Goh, V Jacobs, C Ng, SM Strauss, VY Hawkins, MA Muirhead, R |
| author_sort | Bluemke, E |
| collection | OXFORD |
| description | <p><strong>Background and Purpose:</strong><br />
Oxygen-enhanced magnetic resonance imaging (MRI) and T1-mapping was used to explore its effectiveness as a prognostic imaging biomarker for chemoradiotherapy outcome in anal squamous cell carcinoma.</p><br />
<p><strong>Materials and Methods:</strong><br />
T2-weighted, T1 mapping, and oxygen-enhanced T1 maps were acquired before and after 8–10 fractions of chemoradiotherapy and examined whether the oxygen-enhanced MRI response relates to clinical outcome. Patient response to treatment was assessed 3 months following completion of chemoradiotherapy. A mean T1 was extracted from manually segmented tumour regions of interest and a paired two-tailed t-test was used to compare changes across the patient population. Regions of subcutaneous fat and muscle tissue were examined as control ROIs.</p><br />
<p><strong>Results:</strong><br />
There was a significant increase in T1 of the tumour ROIs across patients following the 8–10 fractions of chemoradiotherapy (paired t-test, p < 0.001, n = 7). At baseline, prior to receiving chemoradiotherapy, there were no significant changes in T1 across patients from breathing oxygen (n = 9). In the post-chemoRT scans (8–10 fractions), there was a significant decrease in T1 of the tumour ROIs across patients when breathing 100% oxygen (paired t-test, p < 0.001, n = 8). Out of the 12 patients from which we successfully acquired a visit 1 T1-map, only 1 patient did not respond to treatment, therefore, we cannot correlate these results with clinical outcome.</p><br />
<p><strong>Conclusions:</strong><br />
These clinical data demonstrate feasibility and potential for T1-mapping and oxygen enhanced T1-mapping to indicate perfusion or treatment response in tumours of this nature. These data show promise for future work with a larger cohort containing more non-responders, which would allow us to relate these measurements to clinical outcome.</p> |
| first_indexed | 2024-03-06T18:16:20Z |
| format | Journal article |
| id | oxford-uuid:04bb8af0-8a7b-4671-a688-aaae26805ff6 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T18:16:20Z |
| publishDate | 2020 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:04bb8af0-8a7b-4671-a688-aaae26805ff62022-03-26T08:53:25ZOxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinomaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:04bb8af0-8a7b-4671-a688-aaae26805ff6EnglishSymplectic ElementsElsevier2020Bluemke, EBulte, DBertrand, AGeorge, BCooke, RChu, K-YDurrant, LGoh, VJacobs, CNg, SMStrauss, VYHawkins, MAMuirhead, R<p><strong>Background and Purpose:</strong><br /> Oxygen-enhanced magnetic resonance imaging (MRI) and T1-mapping was used to explore its effectiveness as a prognostic imaging biomarker for chemoradiotherapy outcome in anal squamous cell carcinoma.</p><br /> <p><strong>Materials and Methods:</strong><br /> T2-weighted, T1 mapping, and oxygen-enhanced T1 maps were acquired before and after 8–10 fractions of chemoradiotherapy and examined whether the oxygen-enhanced MRI response relates to clinical outcome. Patient response to treatment was assessed 3 months following completion of chemoradiotherapy. A mean T1 was extracted from manually segmented tumour regions of interest and a paired two-tailed t-test was used to compare changes across the patient population. Regions of subcutaneous fat and muscle tissue were examined as control ROIs.</p><br /> <p><strong>Results:</strong><br /> There was a significant increase in T1 of the tumour ROIs across patients following the 8–10 fractions of chemoradiotherapy (paired t-test, p < 0.001, n = 7). At baseline, prior to receiving chemoradiotherapy, there were no significant changes in T1 across patients from breathing oxygen (n = 9). In the post-chemoRT scans (8–10 fractions), there was a significant decrease in T1 of the tumour ROIs across patients when breathing 100% oxygen (paired t-test, p < 0.001, n = 8). Out of the 12 patients from which we successfully acquired a visit 1 T1-map, only 1 patient did not respond to treatment, therefore, we cannot correlate these results with clinical outcome.</p><br /> <p><strong>Conclusions:</strong><br /> These clinical data demonstrate feasibility and potential for T1-mapping and oxygen enhanced T1-mapping to indicate perfusion or treatment response in tumours of this nature. These data show promise for future work with a larger cohort containing more non-responders, which would allow us to relate these measurements to clinical outcome.</p> |
| spellingShingle | Bluemke, E Bulte, D Bertrand, A George, B Cooke, R Chu, K-Y Durrant, L Goh, V Jacobs, C Ng, SM Strauss, VY Hawkins, MA Muirhead, R Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma |
| title | Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma |
| title_full | Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma |
| title_fullStr | Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma |
| title_full_unstemmed | Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma |
| title_short | Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma |
| title_sort | oxygen enhanced mri molli t1 mapping during chemoradiotherapy in anal squamous cell carcinoma |
| work_keys_str_mv | AT bluemkee oxygenenhancedmrimollit1mappingduringchemoradiotherapyinanalsquamouscellcarcinoma AT bulted oxygenenhancedmrimollit1mappingduringchemoradiotherapyinanalsquamouscellcarcinoma AT bertranda oxygenenhancedmrimollit1mappingduringchemoradiotherapyinanalsquamouscellcarcinoma AT georgeb oxygenenhancedmrimollit1mappingduringchemoradiotherapyinanalsquamouscellcarcinoma AT cooker oxygenenhancedmrimollit1mappingduringchemoradiotherapyinanalsquamouscellcarcinoma AT chuky oxygenenhancedmrimollit1mappingduringchemoradiotherapyinanalsquamouscellcarcinoma AT durrantl oxygenenhancedmrimollit1mappingduringchemoradiotherapyinanalsquamouscellcarcinoma AT gohv oxygenenhancedmrimollit1mappingduringchemoradiotherapyinanalsquamouscellcarcinoma AT jacobsc oxygenenhancedmrimollit1mappingduringchemoradiotherapyinanalsquamouscellcarcinoma AT ngsm oxygenenhancedmrimollit1mappingduringchemoradiotherapyinanalsquamouscellcarcinoma AT straussvy oxygenenhancedmrimollit1mappingduringchemoradiotherapyinanalsquamouscellcarcinoma AT hawkinsma oxygenenhancedmrimollit1mappingduringchemoradiotherapyinanalsquamouscellcarcinoma AT muirheadr oxygenenhancedmrimollit1mappingduringchemoradiotherapyinanalsquamouscellcarcinoma |